Author

Sandra Wear

Observed names: Sandra M. Wear, Sandra Marija Wear

Institution: Multiple Myeloma Research Foundation

Observed institution: Multiple Myeloma Research Foundation

OpenAlex ID: A5043963551

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

2012 · David S. Siegel, Thomas Martin, et al. · Blood · 657

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

2012 · Ravi Vij, Michael Wang, et al. · Blood · 255

An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

2012 · Ravi Vij, David S. Siegel, et al. · British Journal of Haematology · 177

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

2012 · Paul G. Richardson, David Siegel, et al. · Blood · 162

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

2011 · Andrzej J. Jakubowiak, Kent A. Griffith, et al. · Blood · 88

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

2011 · Paul G. Richardson, Andrew Spencer, et al. · Blood · 64

Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial

2011 · David S. Siegel, Meletios Athanasios Dimopoulos, et al. · Blood · 45

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)

2011 · Andrzej J Jakubowiak, Dominik Dytfeld, et al. · Blood · 24

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.

2009 · Andrzej J. Jakubowiak, Donna E. Reece, et al. · Blood · 18

Final Results From the Bortezomib-naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

2011 · Ravi Vij, Jonathan L. Kaufman, et al. · Blood · 11

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

2008 · Paul Richardson, Craig C. Hofmeister, et al. · Blood · 10

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

2011 · Andrzej J Jakubowiak, David S. Siegel, et al. · Blood · 7

The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.

2010 · Sandra Wear, Paul G. Richardson, et al. · Blood · 2

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

2010 · Andrzej J Jakubowiak, Donna E. Reece, et al. · Blood · 1

Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).

2012 · Andrzej J. Jakubowiak, Kent A. Griffith, et al. · Journal of Clinical Oncology

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development

2011 · Sandra M. Wear, Paul G. Richardson, et al. · Blood

Abstract B58: Decreasing the time to activate clinical trials: Initial data from the Multiple Myeloma Research Consortium (MMRC) model

2009 · Sandra Wear, Susan Kelley, et al. · Molecular Cancer Therapeutics

Works count: 17

Citation count: 1,521

H-index: 10

I10-index: 11